Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662149 | 0.82 | AADAT (0.40) | AADATCYP2C19KMT2APTGER3ALDH1A1 | |
| SCHEMBL5001527 | 0.78 | CHRM1 (0.39) | AADATCHRM1KMT2APTGER3ALDH1A1 | |
| SCHEMBL661031 | 0.78 | KMT2A (0.36) | KMT2APTGER3ALDH1A1RAB9A | |
| SCHEMBL4992293 | 0.77 | CHRM1 (0.38) | AADATCHRM1KMT2APTGER3ALDH1A1 | |
| SCHEMBL2825414 | 0.77 | AADAT (0.41) | AADATCYP2C19CHRM1KMT2AALDH1A1 | |
| SCHEMBL578432 | 0.75 | NOTUM (0.50) | CYP2C19KMT2AALDH1A1NOTUMMAPT | |
| SCHEMBL9834735 | 0.73 | CHRM1 (0.46) | CHRM1NOTUMMAPT | |
| SCHEMBL11645408 | 0.73 | KMT2A (0.59) | CYP2C19KMT2AALDH1A1RAB9ATDP1 | |
| SCHEMBL18188521 | 0.73 | AADAT (0.44) | AADATKMT2ANOTUMTDP1 | |
| SCHEMBL661264 | 0.71 | PER2 (0.42) | CHRM1KMT2AALDH1A1NOTUMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| CN-100364973-C | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2008-01-30 | — | — | CN | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | disclosed |
| EP-1620399-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004087658-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | AADAT 26/4885CYP2C19 69/4885TRPA1 909/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | AADAT 26/4885CYP2C19 69/4885TRPA1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.